Clinical Trial Update: In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial update describing the use of allogeneic Epstein-Barr virus-specific cytotoxic T-lymphocytes targeted to CD19 for B-cell malignancies; currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoma

Drugs mentioned

• EBV-CTLs targeting CD19 (epstein-barr virus-specific cytotoxic T-lymphocytes targeting CD19)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Lymphocytic Leukemia, Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING